Cantor Fitzgerald Weighs in on ELDN FY2025 Earnings

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Investment analysts at Cantor Fitzgerald dropped their FY2025 earnings estimates for Eledon Pharmaceuticals in a research note issued to investors on Monday, March 24th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will post earnings of ($1.23) per share for the year, down from their prior forecast of ($1.12). The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share.

Separately, Guggenheim began coverage on shares of Eledon Pharmaceuticals in a research report on Tuesday, January 28th. They set a “buy” rating and a $9.00 target price on the stock.

Eledon Pharmaceuticals Price Performance

Shares of NASDAQ ELDN opened at $3.47 on Wednesday. Eledon Pharmaceuticals has a one year low of $1.52 and a one year high of $5.54. The firm has a market cap of $207.79 million, a price-to-earnings ratio of -1.73 and a beta of 0.80. The stock’s fifty day moving average price is $4.15 and its two-hundred day moving average price is $3.89.

Eledon Pharmaceuticals (NASDAQ:ELDN) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.32). During the same period in the previous year, the business posted ($1.00) EPS.

Institutional Investors Weigh In On Eledon Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC boosted its stake in shares of Eledon Pharmaceuticals by 418.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,944 shares of the company’s stock valued at $33,000 after purchasing an additional 6,412 shares in the last quarter. Alpine Global Management LLC acquired a new stake in Eledon Pharmaceuticals during the 4th quarter worth approximately $56,000. ADAR1 Capital Management LLC bought a new stake in Eledon Pharmaceuticals during the 4th quarter worth approximately $66,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Eledon Pharmaceuticals in the 4th quarter valued at approximately $76,000. Finally, Virtu Financial LLC bought a new position in shares of Eledon Pharmaceuticals during the fourth quarter valued at $82,000. Institutional investors own 56.77% of the company’s stock.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).